Skip to main content

Table 3 Toxicity (N = 19)

From: A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

Event

Grade

1

2

3

4

Grade 3/4 (%)

White blood cell decrease

12

2

0

0

0

Neutrophil decrease

3

2

7

2

9 (47)

Febrile neutropenia

0

0

0

Anemia

8

5

2

0

2 (11)

Platelet count decrease

3

1

1

0

1 (5)

 

Grade 2/3/4 (%)

Nausea

3

2

0

0

2 (11)

Vomiting

1

0

0

0

0

Mucositis oral

2

0

0

0

0

GI perforation

0

0

0

0

0

Sensory neuropathy

3

1

0

0

1 (5)

Motor neuropathy

0

0

0

0

0

Hypertension

7

2

1

0

3 (16)

Protein urea

8

3

1

0

4 (21)

Fatigue

3

0

0

0

0

AST/ALT increase

3

0

2

0

2 (11)

Thromboembolic event

0

0

1

0

1 (5)

Nasal bleeding

0

1

0

0

1 (5)

Interstitial pneumonia

0

0

1

0

1 (5)

  1. Common Terminology Criteria for Adverse Events v4.0
  2. GI gastrointestinal, AST aspartate aminotransferase, ALT alanine aminotransferase